Interestingly the information about metformin targeting DPP-4 is scarce, and mostly points out co-treatment of a combination of DPP-4 inhibitors (gliptins) and metformin in diabetes and/or mild to moderate hypertension (Mistry et al., 2008; Scheen, 2017). The gene discussed is DPP4; the disease is diabetes mellitus.